









Märkte
/
Aktien
/
nasdaq-vrna
/

Verona Pharma PLC

VRNA

106.910USD

0.000

Handelsschluss 10/30, 16:00（ET）Kurse um 15 Minuten verzögert

73.55BMarktkapitalisierung

VerlustKGV TTM



Verona Pharma PLC

106.910

0.000

Übersicht Unternehmen Finanzen Analyse

Übersicht

Unternehmen

Finanzen

Analyse

mehr Informationen über Verona Pharma PLC Unternehmen

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Verona Pharma PLC Informationen



BörsenkürzelVRNA

Name des UnternehmensVerona Pharma PLC

IPO-datumMar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

Anzahl der mitarbeiter209

WertpapierartDepository Receipt

GeschäftsjahresendeMar 30

AddresseRiverside

StadtLONDON

BörseNASDAQ Global Market Consolidated

LandUnited Kingdom

PostleitzahlSE1 2RE

Telefon442032834200

Websitehttps://www.veronapharma.com/

BörsenkürzelVRNA

IPO-datumMar 30, 2005

CEODr. David S. Zaccardelli, Pharm.D.

Führungskräfte von Verona Pharma PLC



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Andrew Fisher

General Counsel

528.82K

+3488.37%

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

Mr. Ben Harber

Company Secretary

Dr. Anders Ullman, M.D., Ph.D.

Non-Executive Independent Director

Mr. Benjamin Lucas

Principal Executive Officer, Director

Ms. Ebru Can Temucin

Principal Financial Officer, Principal Accounting Officer, Director

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Andrew Fisher

General Counsel

528.82K

+3488.37%

Dr. Kathleen Rickard, M.D.

Chief Medical Officer

Mr. Ben Harber

Company Secretary

Dr. Anders Ullman, M.D., Ph.D.

Non-Executive Independent Director

Mr. Benjamin Lucas

Principal Executive Officer, Director

Ms. Ebru Can Temucin

Principal Financial Officer, Principal Accounting Officer, Director

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Wed, Oct 29

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

Andere

74.07%

Aktionäre

Anteil

Janus Henderson Investors

7.12%

Perceptive Advisors LLC

6.39%

Darwin Global Management Ltd

4.79%

Frazier Life Sciences Management, L.P.

3.93%

Ali (Behbahani)

3.70%

Andere

74.07%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

26.30%

Investment Advisor/Hedge Fund

25.53%

Investment Advisor

18.19%

Private Equity

10.42%

Individual Investor

5.62%

Venture Capital

4.96%

Research Firm

4.39%

Family Office

1.17%

Pension Fund

0.15%

Andere

3.28%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

455

78.51M

91.09%

-4.37M

2025Q2

423

82.86M

96.18%

-3.71M

2025Q1

406

83.91M

98.59%

+940.31K

2024Q4

326

71.46M

84.46%

-16.29M

2024Q3

290

72.06M

88.66%

-13.37M

2024Q2

265

71.81M

88.57%

-10.49M

2024Q1

244

72.12M

89.24%

-7.07M

2023Q4

230

69.67M

87.15%

-7.79M

2023Q3

210

67.04M

84.35%

-7.14M

2023Q2

205

65.57M

82.53%

-8.85M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Janus Henderson Investors

6.13M

7.12%

+617.52K

+11.19%

Jun 30, 2025

Perceptive Advisors LLC

5.51M

6.39%

-1.06M

-16.09%

Jun 30, 2025

Darwin Global Management Ltd

4.13M

4.79%

+206.41K

+5.26%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

3.38M

3.93%

-73.90K

-2.14%

Jun 30, 2025

Ali (Behbahani)

3.19M

3.7%

+3.19M

Jan 16, 2025

RTW Investments L.P.

3.05M

3.54%

+203.08K

+7.13%

Jun 30, 2025

Eventide Asset Management, LLC

2.72M

3.15%

-178.11K

-6.16%

Jun 30, 2025

Goldman Sachs & Company, Inc.

2.61M

3.03%

+1.58M

+152.32%

Jun 30, 2025

New Enterprise Associates (NEA)

2.26M

2.63%

-425.43K

-15.82%

Jun 30, 2025

Summit Partners Public Asset Management, LLC

2.14M

2.49%

-178.83K

-7.70%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

AltShares Merger Arbitrage ETF

4.07%

ProShares Merger ETF

2.84%

First Trust IPOX Europe Equity Opportunities ETF

2.75%

NYLI Merger Arbitrage ETF

2.6%

AltShares Event-Driven ETF

2.5%

First Trust International Equity Opportunities ETF

1.92%

Global X Guru Index ETF

1.23%

ProShares Ultra Nasdaq Biotechnology

0.85%

Invesco Nasdaq Biotechnology ETF

0.85%

iShares Biotechnology ETF

0.5%

AltShares Merger Arbitrage ETF

Anteil4.07%

ProShares Merger ETF

Anteil2.84%

First Trust IPOX Europe Equity Opportunities ETF

Anteil2.75%

NYLI Merger Arbitrage ETF

Anteil2.6%

AltShares Event-Driven ETF

Anteil2.5%

First Trust International Equity Opportunities ETF

Anteil1.92%

Global X Guru Index ETF

Anteil1.23%

ProShares Ultra Nasdaq Biotechnology

Anteil0.85%

Invesco Nasdaq Biotechnology ETF

Anteil0.85%

iShares Biotechnology ETF

Anteil0.5%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI

